Metraipolis › archive › dc_cc29c97364ca
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 — Europe PMC PPR:PPR151409
- Source
- Europe PMC
- Original
- https://europepmc.org/article/PPR/PPR151409
- DOI
- 10.1101/2020.04.15.043166
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-09T00:28:39.287Z
- SHA-256 of the archived text
c81ff35df050676b62cee5878b1a2cd91c40c075ca4c9de0abe35908555466bf- Stable URL of this page
https://metraipolis.com/documento/dc_cc29c97364ca
How to cite
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 — Europe PMC PPR:PPR151409 — Europe PMC, https://europepmc.org/article/PPR/PPR151409 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_cc29c97364ca (Metraipolis archive dc_cc29c97364ca, sha256 c81ff35df050676b62cee5878b1a2cd91c40c075ca4c9de0abe35908555466bf)
BibTeX
@misc{dccc29c97364ca,
title = {Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 — Europe PMC PPR:PPR151409},
howpublished = {Europe PMC},
url = {https://europepmc.org/article/PPR/PPR151409},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_cc29c97364ca; sha256 c81ff35df050676b62cee5878b1a2cd91c40c075ca4c9de0abe35908555466bf},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR151409. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Effective therapeutics to treat COVID-19 are urgently needed. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. Here, we tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection. Methods: To evaluate the effect of remdesivir treatment on SARS-CoV-2 disease outcome, we used the recently established rhesus macaque model of SARS-CoV-2 infection that results in transient lower respiratory tract disease. Two groups of six rhesus macaques were infected with SARS-CoV-2 and treated with intravenous remdesivir or an equal volume of vehicle solution once daily. Clinical, virological and histological parameters were assessed regularly during the study and at necropsy to determine treatment efficacy. Results: In contrast to vehicle-treated animals, animals treated with remdesivir did not show signs of respiratory disease and had reduced pulmonary infiltrates on radiographs. Virus titers in bronchoalveolar lavages were significantly reduced as early as 12hrs after the first treatment was administered. At necropsy on day 7 after inoculation, lung viral loads of remdesivir-treated animals were significantly lower and there was a clear reduction in damage to the lung tissue. Conclusions: Therapeutic remdesivir treatment initiated early during infection has a clear clinical benefit in SARS-CoV-2-infected rhesus macaques. These data support early remdesivir treatment initiation in COVID-19 patients to prevent progression to severe pneumonia. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: bioRxiv, 2020 (prima pubblicazione 2020-04-15). Identificativi: DOI 10.1101/2020.04.15.043166. Pagina: https://europepmc.org/article/PPR/PPR151409 — https://doi.org/10.1101/2020.04.15.043166. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-09T00:25:21.054Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.